Single-Cell Analysis Reveals SLC7A1's Role in Osteosarcoma P
2026-07-08
Liao et al. employed single-cell and bulk transcriptomic profiling to identify the solute carrier SLC7A1 as a key driver of osteosarcoma malignancy and immune modulation. Their integrative methodology revealed SLC7A1's association with poor prognosis, tumor proliferation, and macrophage polarization, providing a new potential target for therapeutic intervention.
EdU Flow Cytometry Assay Kits (Cy3): Next-Gen Cell Cycle Ana
2026-07-07
The EdU Flow Cytometry Assay Kits (Cy3) empower researchers with precise, denaturation-free measurement of DNA synthesis, enabling robust cell proliferation and genotoxicity studies. Leveraging click chemistry, these kits streamline S-phase detection and multiplexing, setting a new benchmark for cell cycle analysis by flow cytometry.
Annexin V-FITC/7-AAD Apoptosis Kit: Sensitive Cell Death Det
2026-07-07
The Annexin V-FITC/7-AAD Apoptosis Kit provides rapid, dual-parameter detection of apoptotic and necrotic cells, enabling reliable cell viability and cytotoxicity assays. Its mechanism leverages phosphatidylserine exposure and DNA permeability to distinguish cell death stages. This kit is widely validated for use in standard apoptosis research workflows.
VNERi: A Refined Index for Vascular Responsiveness in Septic
2026-07-06
Goury et al. introduce VNERi, a novel bedside index that adjusts diastolic arterial pressure for both heart rate and norepinephrine dose, showing it outperforms previous markers in predicting outcomes in early septic shock. This approach offers improved stratification of vascular responsiveness, with implications for individualized therapy decisions.
Doxorubicin (SKU A3966): Reliable Chemotherapy Research Solu
2026-07-06
This article presents an evidence-based exploration of Doxorubicin (SKU A3966) as a reference chemotherapeutic agent for cell viability, proliferation, and cytotoxicity assays. Through scenario-driven Q&A, it addresses common laboratory challenges and demonstrates how APExBIO's Doxorubicin delivers reproducibility, sensitivity, and workflow compatibility, supporting robust cancer biology research.
Bifendate (DDB): Mechanistic Precision for Translational Liv
2026-07-05
Explore how Bifendate (DDB), a synthetic Schisandrin C derivative, redefines hepatoprotection through multifaceted mechanisms—spanning autophagy inhibition, CYP3A4 modulation, and lipid metabolism regulation. This article bridges rigorous mechanistic evidence with actionable strategy, empowering translational researchers to design robust, clinically meaningful studies in metabolic and inflammatory liver disease.
MK-1775: Wee1 Kinase Inhibitor Workflows for Cancer Research
2026-07-04
MK-1775, a potent Wee1 kinase inhibitor from APExBIO, provides researchers with a precise tool to abrogate the G2 DNA damage checkpoint, enabling robust sensitization of p53-deficient tumor cells in preclinical cancer models. This article delivers actionable workflows, advanced troubleshooting, and key protocol enhancements rooted in the latest systems biology insights.
CRISPR Activation Unmasks Splice-Altering Variants in Diagno
2026-07-03
Terkelsen et al. (2024) introduce a CRISPR activation (CRISPRa) platform enabling functional analysis of splice-altering variants in genes not natively expressed in accessible cells like skin fibroblasts. This approach overcomes a major limitation in rare disease diagnostics, allowing direct assessment of variant impact on splicing patterns using widely available laboratory tools.
Sulforaphane Suppresses NLRP3 Inflammasome in Colitis Models
2026-07-03
This study demonstrates that sulforaphane, a natural isothiocyanate, reduces oxidative stress and inhibits NLRP3 inflammasome activation in a dextran sodium sulfate-induced mouse model of ulcerative colitis. These mechanistic insights clarify sulforaphane’s anti-inflammatory action, supporting its utility for modeling and dissecting oxidative stress and inflammasome pathways in inflammatory disease research.
Sulfaphenazole: CYP2C9 Inhibitor Benchmarks & Biomedical Use
2026-07-02
Sulfaphenazole is a selective CYP2C9 inhibitor with validated antibacterial and vascular research applications. Its potency, safety, and cross-domain impact are supported by peer-reviewed studies and product data. This article clarifies efficacy parameters and common misconceptions for practitioners.
WM-8014 KAT6A Inhibitor: Precision Workflows for Cancer Biol
2026-07-02
WM-8014 stands out as a selective, reversible KAT6A inhibitor, empowering cancer and epigenetic researchers to dissect senescence pathways with minimal cytotoxicity. This guide delivers actionable protocols, troubleshooting insights, and advanced applications inspired by recent breakthroughs like RESTRICT-seq, unlocking the full translational power of WM-8014 in the lab.
Brefeldin A: Driving ER Stress & Cancer Cell Apoptosis Resea
2026-07-01
Brefeldin A (BFA) is a gold-standard tool for disrupting ER-to-Golgi trafficking, unlocking advanced insights into ER stress, apoptosis induction in cancer cells, and endothelial injury mechanisms. This guide offers a workflow-centric approach, protocol parameters, and troubleshooting strategies for maximizing BFA’s impact in cancer and translational cell biology.
Vitamin C (CAS 50-81-7): Reliable Solutions for Cell Assays
2026-07-01
This article addresses key laboratory challenges in cell viability and proliferation assays, demonstrating how Vitamin C (CAS 50-81-7, SKU B2064) supports reproducible, data-driven research. Drawing on validated protocols and peer-reviewed evidence, it guides researchers in optimizing their workflows with APExBIO’s high-purity ascorbic acid.
SP600125: Advanced JNK Inhibitor Workflows for Inflammation
2026-06-30
SP600125 from APExBIO is a highly selective JNK inhibitor enabling precise dissection of apoptosis, cytokine modulation, and inflammation pathways. This guide delivers actionable protocols, troubleshooting insights, and domain-bridging strategies for maximizing experimental reproducibility in both in vitro and in vivo models.
NBC19: A Precision NLRP3 Inflammasome Inhibitor for Inflamma
2026-06-30
NBC19 sets a new benchmark as a nanomolar NLRP3 inflammasome inhibitor, enabling highly reproducible investigation of inflammation pathways in cellular models. Its robust modulation of IL-1β release and compatibility with Nigericin- and ATP-induced workflows make it indispensable for dissecting immune responses and optimizing sepsis-related assays.
466 records 13/32 page Previous Next First page 上5页 1112131415 下5页 Last page